Article information
Full text is only aviable in PDF
REFERENCES
[1]
M Modesto-Alapont, D Nauffal-Manzur, E Ansotegui-Barrera, R Menéndez-Villanueva, A Ballesta, R Touza, et al.
¿Puede reducir la mortalidad de los pacientes con EPOC la profilaxis domiciliaria de la enfermedad tromboembólica venosa?.
Arch Bronconeumol, 42 (2006), pp. 130-134
[2]
MM Samama, AT Cohen, JY Darmon, L Desjardins, A Eldor, C Janbon, et al.
A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.
N Engl J Med, 341 (1999), pp. 793-800
[3]
B Lindblad, NH Sternby, D Bergqvist.
Incidence of venous thromboembolism verified by necropsy over 30 years.
BMJ, 302 (1991), pp. 709-711
[4]
PA McKelvie.
Autopsy evidence of pulmonary thromboembolism.
Med J Aust, 160 (1994), pp. 127-128
[5]
J Suchankova, M Mata, J Cortijo, EJ Morcillo.
Effects of bemiparin on airway responses to antigen in sensitized Brown-Norway rats.
Eur J Pharmacol, 507 (2005), pp. 261-271
[6]
European Medicines Agency (EMEA). Committee for Medicinal Products for Human Use (CHMP). Guideline on clinical investigation of medicinal products for the prophylaxis of venous thromboembolic risk in non-surgical patients. Doc. Ref. CPMP/EWP/6235/04. London: EMEA; June 2006
Copyright © 2007. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
